As of 2025-01-23, the Relative Valuation of Cytosorbents Corp (CTSO) is (12.96) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.04 USD, the upside of Cytosorbents Corp based on Relative Valuation is -1346.6%.
The range of the Relative Valuation is (13.88) - (13.40) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 40.8x - 43.3x | 41.5x |
| Forward P/E multiples | 29.7x - 39.3x | 34.6x |
| Fair Price | (13.88) - (13.40) | (12.96) |
| Upside | -1434.5% - -1388.0% | -1346.6% |
| Date | P/E |
| 2025-01-13 | -3.08 |
| 2025-01-10 | -2.75 |
| 2025-01-08 | -2.85 |
| 2025-01-07 | -2.97 |
| 2025-01-06 | -3.05 |
| 2025-01-03 | -2.75 |
| 2025-01-02 | -2.70 |
| 2024-12-31 | -2.67 |
| 2024-12-30 | -2.64 |
| 2024-12-27 | -2.76 |
| 2024-12-26 | -2.64 |
| 2024-12-24 | -2.62 |
| 2024-12-23 | -2.46 |
| 2024-12-20 | -2.69 |
| 2024-12-19 | -2.58 |
| 2024-12-18 | -2.52 |
| 2024-12-17 | -2.38 |
| 2024-12-16 | -2.67 |
| 2024-12-13 | -2.97 |
| 2024-12-12 | -2.62 |
| 2024-12-11 | -2.59 |
| 2024-12-10 | -2.56 |
| 2024-12-09 | -2.58 |
| 2024-12-06 | -2.68 |
| 2024-12-05 | -2.72 |
| 2024-12-04 | -2.83 |
| 2024-12-03 | -2.79 |
| 2024-12-02 | -2.94 |
| 2024-11-29 | -2.85 |
| 2024-11-27 | -2.67 |
| 2024-11-26 | -2.64 |
| 2024-11-25 | -2.73 |
| 2024-11-22 | -2.70 |
| 2024-11-21 | -2.61 |
| 2024-11-20 | -2.69 |
| 2024-11-19 | -2.82 |
| 2024-11-18 | -2.73 |
| 2024-11-15 | -2.63 |
| 2024-11-14 | -2.79 |
| 2024-11-13 | -2.72 |
| 2024-11-12 | -2.85 |
| 2024-11-11 | -2.73 |
| 2024-11-08 | -2.17 |
| 2024-11-07 | -2.65 |
| 2024-11-06 | -2.70 |
| 2024-11-05 | -2.53 |
| 2024-11-04 | -2.56 |
| 2024-11-01 | -2.94 |
| 2024-10-31 | -2.97 |
| 2024-10-30 | -2.97 |